March 11, 2011 | by Actelion Pharmaceuticals Ltd
|
Reading time: 2 minutes
March 11, 2011, Actelion Ltd (SIX: ATLN) is pleased to announce that its Executive Team was ranked 2nd "Most Honoured Company" overall in the in the 2011 Institutional Investor All-Europe Awards [alongside another Swiss company, Holcim.] Actelion was ranked as the 3rd Most Honoured Company in 2010.
The results of the Institutional Investor survey reflect the opinions from more than 800 investment professionals at 435 buy-side firms and more than 1,200 sell-side analysts from almost 150 institutions about the executive teams of European companies.
The "Most Honoured Company" the award is based on the votes received for the Executive Team across a total of four categories: Best CEO, Best CFO, Best IR Officer and Best Company IR Overall.
Within the Biotechnology sector, Actelion made a clean sweep of the awards with Jean- Paul Clozel ranking 1st amongst the sectors CEOs, Andrew J. Oakley ranking 1st amongst the sectors CFOs and Roland Haefeli ranking 1st in the IR Officer category. As a result Actelion ranked as the leading Biotechnology Company in the 2011 Institutional Investor All European Executive Team award.
Jean-Paul Clozel: "We are pleased to have received this positive feedback from shareholders and the broader European investment community. We place a great deal of emphasis on our investor relations activities which are focused on being fully transparent on our strategy and operational performance. The result of this survey has also been reflected in the strong support for our strategy that we have received during our recent discussions with shareholders."
Contact:
Roland Haefeli
Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd
Gewerbestrasse 16
CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
www.actelion.com
Editor's note: Image rights belong to the respective publisher.
Conclusion of this article: « The Actelion's Management Honoured in 2011 Institutional Investors All-Europe Executive Team Awards »
Source: Actelion Pharmaceuticals Ltd, Press release